In late November, the drugmaker filed suit against two Florida compounding pharmacies, Wells Pharmacy and Brooksville Pharmaceuticals, alleging they sell semaglutide therapies containing impurities up to 33% of the product.
The lawsuits are the latest in a series of litigation across the U.S. In June, Novo Nordisk filed lawsuits against six spas and clinics, and the next month saw filed suits against three compounding pharmacies.
The FDA is currently investigating schemes that sell counterfeit versions of Ozempic to unsuspecting pharmacies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.